Artia Global Partners »

Rapport Therapeutics shares owned by Artia Global Partners

Quarter-by-quarter ownership of Rapport Therapeutics (RAPP) shares owned by Artia Global Partners from 13F filings

Historical chart of Artia Global Partners investment in Rapport Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Rapport Therapeutics held by Artia Global Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Rapport Therapeutics by Artia Global Partners

Quarter filed Position value Share count Share price at filing
2025-12-31 $4.2M 139k 30.34
2025-09-30 $1.9M 65k 29.70

More positions owned by Artia Global Partners

Insmed Com Par $.01 (INSM)
Abivax Sa Sponsored Ads (ABVX)
Argenx Se Sponsored Adr (ARGX)
Eli Lilly & Co. (LLY)
Proshares Tr Ii Ultra Gold (UGL)
Soleno Therapeutics (SLNO)
Viking Therapeutics (VKTX)
Trevi Therapeutics (TRVI)
Uniqure Nv SHS (QURE)
Newamsterdam Pharma Company Ordinary Shares (NAMS)
Astrazeneca Sponsored Adr
Cidara Therapeutics Com New (CDTX)
Eyepoint Pharmaceuticals Com New (EYPT)
Ionis Pharmaceuticals (IONS)
Dianthus Therapeutics (DNTH)

View all positions for Artia Global Partners

Top funds holding Rapport Therapeutics

TRV GP V
FMR
Arch Venture Corp
Capital Research and Management Company - Division 3
Cormorant Asset Management
Goldman Sachs Group
BlackRock
Sofinnova Ventures
Vanguard Group
Johnson & Johnson
Baker Bros. Advisors
Vestal Point Capital
Polar Capital Holdings
Trv Gp Vi
Ubs Global Asset Management Americas

View all funds holding Rapport Therapeutics